Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor

Executive Summary

Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force

You may also be interested in...



ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs

The ALLHAT hypertension trial is bringing renewed calls for more comparative trials of pharmaceutical agents

ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs

The ALLHAT hypertension trial is bringing renewed calls for more comparative trials of pharmaceutical agents

Novartis Diovan Gets Heart Failure Claim But Is Second Line To ACE Inhibitors

Novartis' Diovan approval for the treatment of heart failure makes the drug the first angiotensin II receptor blocker to carry the indication, but limits it to patients who cannot take ACE inhibitors

Related Content

UsernamePublicRestriction

Register

PS039757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel